Greenlane to Launch Fentanyl, Xylazine and Drink Spike Detection Test Strips Product Line
Greenlane Holdings, Inc. (NASDAQ:GNLN) has announced plans to launch a new line of fentanyl, xylazine, and drink spike detection test strips under the Safety Strips, Inc. brand. The products will be available for order from September 25th through Greenlane's online retail storefronts and wholesale portal, with shipments starting October 1st. This initiative aims to address the growing opioid epidemic and the rising incidence of drink spiking.
The company will leverage its distribution, operations, marketing, and sales teams to support the brand. This move aligns with California's new Assembly Bill No. 1013, which requires clubs and bars to offer drug testing devices for detecting controlled substances in drinks. Greenlane's CEO, Barbara Sher, emphasized the company's commitment to safety and improving lives through this partnership with Safety Strips, Inc.
Greenlane Holdings, Inc. (NASDAQ:GNLN) ha annunciato l'intenzione di lanciare una nuova linea di strisce di test per la rilevazione di fentanyl, xylazine e delle bevande adulterate con il marchio Safety Strips, Inc. I prodotti saranno disponibili per ordini dal 25 settembre attraverso i negozi online di Greenlane e il portale all'ingrosso, con spedizioni a partire dal 1° ottobre. Questa iniziativa mira a combattere l'epidemia crescente di oppioidi e il aumento dei casi di bevande adulterate.
L'azienda utilizzerà i propri team di distribuzione, operazioni, marketing e vendita per supportare il marchio. Questa mossa è in linea con la nuova legge dell'Assemblea della California n. 1013, che richiede che club e bar offrano dispositivi per testare la presenza di sostanze controllate nelle bevande. La CEO di Greenlane, Barbara Sher, ha sottolineato l'impegno dell'azienda per la sicurezza e il miglioramento della vita attraverso questa partnership con Safety Strips, Inc.
Greenlane Holdings, Inc. (NASDAQ:GNLN) ha anunciado planes para lanzar una nueva línea de tiras de prueba para la detección de fentanilo, xilazina y adulteración de bebidas bajo la marca Safety Strips, Inc. Los productos estarán disponibles para pedidos a partir del 25 de septiembre a través de las tiendas en línea de Greenlane y el portal mayorista, con envíos comenzando el 1 de octubre. Esta iniciativa busca abordar la creciente epidemia de opioides y el aumento de la adulteración de bebidas.
La empresa aprovechará sus equipos de distribución, operaciones, marketing y ventas para apoyar la marca. Este movimiento está alineado con la nueva Ley de la Asamblea de California No. 1013, que requiere que clubes y bares ofrezcan dispositivos de prueba de drogas para detectar sustancias controladas en las bebidas. La CEO de Greenlane, Barbara Sher, enfatizó el compromiso de la empresa con la seguridad y la mejora de vidas a través de esta colaboración con Safety Strips, Inc.
그린레인 홀딩스, 주식회사(NASDAQ:GNLN)는 펜타닐, 시랄리진 및 음료 스파이크 감지 테스트 스트립을 Safety Strips, Inc. 브랜드 하에 출시할 계획을 발표했습니다. 이 제품들은 9월 25일부터 그린레인의 온라인 소매점과 도매 포털을 통해 주문할 수 있으며, 10월 1일부터 배송이 시작됩니다. 이 이니셔티브는 커져가는 오피오이드 전염병과 음료 스파이크 사건 증가에 대응하기 위한 것입니다.
회사는 배급, 운영, 마케팅 및 판매 팀을 활용하여 브랜드를 지원할 것입니다. 이 움직임은 클럽과 바에서 음료의 약물 검출 장치를 제공해야 하는 캘리포니아의 새로운 의회 법안 1013과 일치합니다. 그린레인의 CEO인 바바라 셔는 Safety Strips, Inc.와의 파트너십을 통해 안전성과 사람들의 삶을 개선하겠다는 회사의 의지를 강조했습니다.
Greenlane Holdings, Inc. (NASDAQ:GNLN) a annoncé son intention de lancer une nouvelle gamme de bandes de test pour la détection de fentanyl, xylazine et d'adultération des boissons sous la marque Safety Strips, Inc. Les produits seront disponibles à la commande à partir du 25 septembre via les boutiques en ligne de Greenlane et le portail de gros, avec des expéditions commençant le 1er octobre. Cette initiative vise à lutter contre l'épidémie croissante d'opioïdes et l'augmentation des cas d'adultération de boissons.
L'entreprise s'appuiera sur ses équipes de distribution, d'opérations, de marketing et de vente pour soutenir la marque. Ce mouvement est en ligne avec la nouvelle loi n° 1013 de l'Assemblée de Californie, qui exige que les clubs et les bars offrent des dispositifs de test de drogue pour détecter les substances contrôlées dans les boissons. La PDG de Greenlane, Barbara Sher, a souligné l'engagement de l'entreprise en matière de sécurité et d'amélioration des vies grâce à ce partenariat avec Safety Strips, Inc.
Greenlane Holdings, Inc. (NASDAQ:GNLN) hat Pläne angekündigt, eine neue Linie von Teststreifen zur Erkennung von Fentanyl, Xylazin und Getränkespikungen unter der Marke Safety Strips, Inc. auf den Markt zu bringen. Die Produkte werden ab dem 25. September über Greenlanes Online-Verkaufsstellen und das Großhandelsportal bestellbar sein, wobei die Lieferungen am 1. Oktober beginnen. Diese Initiative zielt darauf ab, der zunehmenden Opioid-Epidemie und der steigenden Häufigkeit von Getränkespikungen entgegenzuwirken.
Das Unternehmen wird seine Vertriebs-, Betriebs-, Marketing- und Verkaufsteams einsetzen, um die Marke zu unterstützen. Dieser Schritt steht im Einklang mit dem neuen Gesetzesentwurf Nr. 1013 der kalifornischen Versammlung, das von Clubs und Bars verlangt, Geräte zur Drogentestung zur Erkennung kontrollierter Substanzen in Getränken anzubieten. Die CEO von Greenlane, Barbara Sher, betonte das Engagement des Unternehmens für Sicherheit und die Verbesserung der Lebensqualität durch diese Partnerschaft mit Safety Strips, Inc.
- Expansion into a new product line addressing critical public health issues
- Alignment with new California legislation, potentially increasing demand
- Leveraging existing distribution and marketing infrastructure for new product line
- Exclusive distribution agreement with Safety Strips, Inc. in the U.S.
- None.
The launch of fentanyl, xylazine and drink spike detection test strips by Greenlane is a significant step in harm reduction efforts. These tools can potentially save lives by allowing users to identify dangerous adulterants in substances. However, it's important to note that these strips are not foolproof and don't detect all possible contaminants.
The timing aligns with California's AB 1013, which mandates drink testing availability in certain establishments. This legislative backing could drive demand and normalize the use of such safety measures. From a public health perspective, while these tools are valuable, they should be part of a comprehensive approach including education, addiction treatment and policy reforms to address the root causes of the opioid epidemic and drink spiking incidents.
Greenlane's expansion into drug detection test strips represents a strategic pivot into a growing market driven by public health concerns. The opioid crisis and increased awareness of drink spiking create a substantial market opportunity. With
Greenlane's existing distribution network and partnerships position it well to capitalize on this opportunity. The company's move aligns with broader harm reduction trends and regulatory shifts, as evidenced by California's AB 1013. This diversification could potentially offset challenges in the cannabis accessories market, providing a new revenue stream in a socially responsible product category.
The launch of drug detection test strips by Greenlane raises interesting legal considerations. While these products aim to enhance safety, companies must be cautious about potential liability issues. False negatives or positives could lead to legal challenges. Additionally, the legal landscape around harm reduction tools varies by jurisdiction, potentially complicating nationwide distribution.
California's AB 1013 sets a precedent that could influence other states to adopt similar legislation, potentially expanding the market for these products. However, Greenlane must navigate complex regulatory environments, ensuring compliance with federal and state laws regarding drug paraphernalia and testing devices. The company should also be prepared for potential pushback from groups concerned about the normalization of drug use.
Portfolio includes Safety Strips, Inc.'s low-cost test strip that provides an affordable, reliable way for people to test substances for two of the dangerous adulterants that are exacerbating the growing opioid epidemic
Drink Spike Test strips meet New California Assembly Bill No 1013, passed July 2024, that requires Clubs and Bars to offer for sale to their customers drug testing devices designed to detect the presence of controlled substances in a drink
Greenlane to leverage its strong distribution, operations, marketing and sales teams to support the brand
BOCA RATON, FL / ACCESSWIRE / September 16, 2024 / Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced its plans to launch an all-new line of fentanyl, xylazine and drink spike detection test strips under the Safety Strips, Inc. ("Safety Strips") brand of drug test strips. Products will be available to order beginning September 25th via the Company's multiple online retail storefronts, (vapor.com, puffitup.com, and higherstandards.com/) as well as its wholesale portal (wholesale.greenlane.com). Shipments will commence October 1 st.
In August, Greenlane announced that it has entered into a non-binding letter of intent to be the exclusive distributor in the U.S., of Safety Strips drug detection test strips. Greenlane has been a trusted partner for some of the most successful and well-known cannabis and lifestyle brands, such as Higher Standards, Marley Natural and K.Haring, providing full sales coverage, marketing, warehousing and logistics services.
"We are delighted to be working with the Safety Strips' team who share our high standards for safety and quality, and our strong focus on improving people's lives and enhancing their safety," said Barbara Sher, Chief Executive Officer for Greenlane. "By combining our extensive sales, marketing, and distribution network with Safety Strips ISO 13485 validated product line of easy, fast, and accurate test strips to detect the presence of various drugs, we can do our part to help prevent accidental overdoses as well as protecting individuals from drug-induced date rape."
The Opioid Epidemic in the United States
According to SHADAC.ORG, "Over the past two decades, the United States has experienced a growing crisis of substance abuse and addiction that is illustrated most starkly by the rise in deaths from drug overdoses. Since 2000, the annual number of overdose deaths from any kind of drug in the U.S. has multiplied nearly six times over, rising from 17,500 to over 106,000 people in 2021. The vast majority of these deaths (about 80,000) involved some form of opioids, including heroin, prescription painkillers, and, most prevalently in recent years, synthetic opioids such as fentanyl. Fentanyl and related synthetic opioids alone accounted for roughly 71,000 drug overdose deaths in 2021, and are also involved in most methamphetamine, cocaine, and prescription opioid overdose deaths-the next most common substances associated with overdose deaths."
The Rising Incidence of Drink Spiking
In a January 2023 article posted on Alcohol.org, it was reported that "According to the Office on Women's Health, date-rape drugs like Rohypnol, GHB, and ketamine are used because they are not easily detected, and victims often do not remember being drugged or assaulted until many hours later. In 2016, there were over 320,000 incidents of rape and sexual assault, and these incidents are often underreported for both women and men. According to RAINN, 11.2 percent of college students experience rape or sexual assault through force, violence, or incapacitation, and in terms of drug-facilitated sexual assault, alcohol is the No. 1 substance for assailants, next to prescription drugs with tranquilizing effects and Rohypnol, ketamine, GHB, and ecstasy."
In response to the rising prevalence of drink spiking, the Californian Assembly passed AB 1013, July 1, 2024. The bill mandates that approximately 2400 establishments with a Type 48 license, which allows the sale of beer, wine, and distilled spirits, must display signage informing patrons that drug testing kits are available.The new law requires businesses to display signs reading, "Don't get roofied! Drink spiking drug test kits are available here. Ask a staff member for details." Establishments must offer these drug testing devices either for sale or free of charge.
About Greenlane Holdings, Inc.
Founded in 2005, Greenlane is a premier global platform for the development and distribution of premium smoking accessories, vape devices, and lifestyle products to thousands of producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. We operate as a powerful family of brands, third-party brand accelerator, and an omnichannel distribution platform.
We proudly offer our own diverse brand portfolio and our exclusively licensed Marley Natural and K.Haring branded products. We also offer a carefully curated set of third-party products through our direct sales channels and our proprietary, owned and operated e-commerce platforms which include Vapor.com, PuffItUp.com, HigherStandards.com, wholesale.greenlane.com and MarleyNaturalShop.com.
For additional information, please visit: https://investor.gnln.com. For additional information, please visit: https://gnln.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Greenlane and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Greenlane has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including those described in our filings with the Securities and Exchange Commission ("SEC"), including under the caption "Risk Factors" in Greenlane's Annual Report on Form 10-K filed for the year ended December 31, 2023 and the Company's other filings with the SEC, which can be obtained on the SEC website at www.sec.gov. These forward-lookingstatements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the SEC.
Investor Contact:
or
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
SOURCE: Greenlane Holdings, Inc.
View the original press release on accesswire.com
FAQ
When will Greenlane (GNLN) launch its fentanyl and drink spike detection test strips?
What types of detection test strips will Greenlane (GNLN) offer?
How does Greenlane's (GNLN) new product line relate to California legislation?
Where will Greenlane (GNLN) sell its new detection test strips?
